IPH2201

DRUG3 trials

Sponsors

Innate Pharma, Canadian Cancer Trials Group, European Organisation for Research and Treatment of Cancer - EORTC

Conditions

Carcinoma, Squamous Cell of Head and NeckGynecologic CancerSquamous Cell Carcinoma of the Oral Cavity

Phase 1

Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity

TerminatedNCT02331875

Innate PharmaSquamous Cell Carcinoma of the Oral Cavity

Start: 2014-12-31End: 2016-12-31Updated: 2017-01-04

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

CompletedNCT02459301

Canadian Cancer Trials GroupGynecologic Cancer

Start: 2015-09-17End: 2019-11-12Updated: 2023-08-04

Phase 2

Biomarker-based Study in R/M SCCHN

European Organisation for Research and Treatment of Cancer - EORTCCarcinoma, Squamous Cell of Head and Neck

Start: 2017-11-16End: 2025-12-31Target: 340Updated: 2023-11-03

Related Papers

Personalized biomarker-based treatment strategy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Results of the biomarker-driven cohorts of the EORTC-HNCG-1559 trial (UPSTREAM).

Journal of Clinical Oncology2025-05-28

Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Journal of Clinical Oncology2023-06-01

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.

2018-12-0150 citations

Abstract 2714: Combination of monalizumab and durvalumab as a potent immunotherapy treatment for solid human cancers

Cancer Research2018-07-016 citations

EORTC 1559-HNCG: A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)—"UPSTREAM".

Journal of Clinical Oncology2018-05-202 citations